FOR IMMEDIATE RELEASE
Coapt Secures New CMS Code for Upper-Limb Pattern Recognition Prostheses
JANUARY 20, 2025 – CHICAGO – Coapt is thrilled to announce that the Centers for Medicare & Medicaid Services (CMS) has created L6700, a Healthcare Common Procedure Coding System (HCPCS) Level II code for adding myoelectric pattern recognition to enhance upper-limb prostheses. Coapt–the pioneer of myoelectric pattern recognition–has been providing its pattern recognition system to the market for over 11 years.
Coapt led a consortium to submit an application to CMS for coverage. HCPCS Level II is a standardized coding system that Medicare and other health insurance programs use to process claims. When CMS assigns a new code, providers can use it to submit a claim for the items described by the code. The addition of a procedure code for pattern recognition will allow for consistent billing and reimbursement for upper limb prosthetic providers and expand access to this transformative technology for upper limb prosthesis users.
The new code–L6700, “Upper extremity addition, external powered feature, myoelectronic control module, additional emg inputs, pattern-recognition decoding intent movement”–covers the Coapt Complete Control interface system and represents the first-of-its-kind code for advanced neurological decoding hardware.
“We believe our myoelectric pattern recognition control system is the most advanced technology in upper limb prosthetics,” said Coapt CEO Blair Lock. “After more than a decade of proven benefit to users, the value and benefit of Coapt’s medical technology has been officially recognized.”
Coapt’s advanced control system is an intent decoder module that unleashes an unprecedented level of personal, intuitive control. It makes prostheses function more naturally for those with upper limb amputation or congenital limb difference.
“This milestone decision from CMS expands the potential patient population who can realistically access Coapt’s intent-decoding technology,” said Coapt Marketing Activation Manager and product user Nicole Marti. “Code coverage opens the door to many more people in the limb difference community who will be able to use Coapt’s control system. They’ll access all the benefits of their prosthesis with greater ease and convenience.”
The new code–L6700” goes into effect on April 1, 2025. CMS payment will be made on a purchase basis. To read the CMS document, click here (pages 116-120)
About Coapt
Coapt, LLC is a privately held company based in Chicago, with a research subsidiary, Liberating Technologies, Inc. in Boston, USA. Coapt was founded in 2012 and quickly launched Complete Control, an FDA Class II-cleared myoelectric, machine learning prosthesis control system. This flagship product—now in its second generation—is the first technology to allow users to naturally control their advanced, prosthetic arms and hands. Complete Control leverages clinically developed artificial intelligence to learn and adapt to users’ unique muscle signal patterns and provide intuitive, intent decoding control for bionic upper limbs. Coapt’s myoelectric pattern recognition products are compatible with more than 450 unique prosthetic limb configurations. In addition to Coapt’s preeminent product line, the company has established deep industry partnerships and a robust academic research portfolio. To learn more, please visit https://coaptengineering.com/.
Media Contact
Molly Summa
molly@mollysummacomms.com
###